

App 's

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 2002:428911 CAPLUS

DN 137:6205

TI Preparation of benzazepinones, isoquinolinones and related compounds as inhibitors of poly(ADP-ribose) polymerase (PARP) for the prevention and/or treatment of tissue damage from cell trauma or cell death due to necrosis or apoptosis.

IN Ferraris, Dana V.; Li, Jia-He; Kalish, Vincent J.; Zhang, Jie

PA Guilford Pharmaceuticals Inc., USA

SO PCT Int. Appl., 152 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044183	A2	20020606	WO 2001-US44815	20011130
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002036521	A5	20020611	AU 2002-36521	20011130
	US 2003022883	A1	20030130	US 2001-996776	20011130
PRAI	US 2000-250132P	P	20001201		
	US 2001-310274P	P	20010809		
	WO 2001-US44815	W	20011130		
OS	MARPAT	137:6205			
GI					




I



II



III




IV


AB This invention discloses the prepn. of title compds. I and II, their pharmaceutically acceptable salts, and related compds. as inhibitors of poly(ADP-ribose) polymerase (PARP) [wherein: A = N, C, CH<sub>2</sub>, CH; B = C, N, NH, S, SO, SO<sub>2</sub>; X = C, CH, N; Y = C, N; Z = C, CH<sub>2</sub>, N, CO; provided that at least one of X, Y, or Z is N; R1, R2, R3, R5 when present are optionally or independently = H, OH, :O, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halogen, amine, COR<sub>8</sub> (R<sub>8</sub> = H, OH, (un)substituted alkyl,

alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl), OR6, NR6R7 (R6, R7 independently = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl); R1, R2, R3, R5 optionally form ring through a straight or branched C1-4alkyl which may addnl. contain 1-2 double or triple bonds; R4 = 1-3 of H, halo, or alkyl; with proviso that when A, X, or Z = C, then R1, R2, R3 when present may also independently = halogen, CN, O; R9, R10, R11, R12 optionally or independently = H, halogen, amino, OH, halo-amine, O-alkyl, O-aryl, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, COR8; R13 = 1-3 of H, halogen, alkoxy, alkyl]. For example, cyclocondensation of formylindazole III (prepd. from Me indole-4-carboxylate and NaNO<sub>2</sub>/AcOH), with hydrazine provided claimed benzoazulenone IV as a white solid. Benzoazulenone IV inhibited human recombinant PARP at an IC<sub>50</sub> of 0.018 .mu.M. PARP IC<sub>50</sub> inhibition studies for an addnl. 156 examples are provided, ranging in values from 0.01 to 20 .mu.M. Biol. data are provided for the in vivo treatment of focal cerebral ischemia and gout via PARP inhibition with selected compds. II. The present invention is believed to protect cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide through inhibition of PARP activity.


IT 433726-67-1P 433726-71-7P 433726-76-2P  
 433726-79-5P 433726-80-8P 433726-81-9P  
 433726-86-4P 433727-89-0P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; prepn. of benzazepinones, isoquinolinones and related compds. as inhibitors of poly(ADP-ribose) polymerase (PARP))  
 RN 433726-67-1 CAPLUS  
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-methoxy- (9CI) (CA INDEX NAME)




RN 433726-71-7 CAPLUS  
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 433726-76-2 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)




RN 433726-79-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 433726-80-8 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 433726-81-9 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-amino- (9CI) (CA INDEX NAME)




RN 433726-86-4 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433727-89-0 CAPLUS  
CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-, 1,1-dimethylethyl ester, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 94191-07-8P, Benzo[c]-1,5-naphthyridin-6(5H)-one

433726-68-2P 433726-69-3P 433726-70-6P  
433726-72-8P 433726-73-9P 433726-74-0P  
433726-75-1P 433726-77-3P 433726-78-4P  
433726-82-0P 433726-83-1P 433726-84-2P  
433726-85-3P 433726-87-5P 433726-88-6P  
433726-89-7P 433726-90-0P 433727-88-9P  
433727-90-3P 433727-91-4P 433727-92-5P  
433727-93-6P 433727-94-7P 433727-95-8P  
433727-96-9P 433727-97-0P 433727-98-1P  
433727-99-2P 433728-00-8P 433728-01-9P  
433728-02-0P 433728-03-1P 433728-04-2P  
433728-05-3P 433728-06-4P 433728-07-5P  
433728-08-6P 433728-09-7P 433728-10-0P  
433728-11-1P 433728-12-2P 433728-13-3P  
433728-14-4P 433728-15-5P 433728-16-6P  
433728-17-7P 433728-18-8P 433728-19-9P  
433728-20-2P 433728-21-3P 433728-22-4P  
433728-23-5P 433728-24-6P 433728-25-7P  
433728-26-8P 433728-27-9P 433728-28-0P  
433728-29-1P 433728-31-5P 433728-32-6P  
433728-33-7P 433728-34-8P 433728-35-9P  
433728-36-0P 433728-37-1P 433728-38-2P  
433728-39-3P 433728-40-6P 433728-41-7P  
433728-42-8P 433728-43-9P 433728-44-0P  
433728-45-1P 433728-46-2P 433728-47-3P  
433728-48-4P 433728-50-8P 433728-51-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of benzazepinones, isoquinolinones and related

compds. as inhibitors of poly(ADP-ribose) polymerase (PARP))


RN 94191-07-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one (9CI) (CA INDEX NAME)




RN 433726-68-2 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 8-methoxy- (9CI) (CA INDEX NAME)




RN 433726-69-3 CAPLUS


CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-chloro- (9CI) (CA INDEX NAME)




RN 433726-70-6 CAPLUS  
CN Benzo[c]-1,5-naphthyridine-2,6-dione, 1,5-dihydro- (9CI) (CA INDEX NAME)




RN 433726-72-8 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-chloro- (9CI) (CA INDEX NAME)




RN 433726-73-9 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-amino- (9CI) (CA INDEX NAME)




RN 433726-74-0 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 433726-75-1 CAPLUS  
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[[3-(diethylamino)propyl]amino]-  
 (9CI) (CA INDEX NAME)



RN 433726-77-3 CAPLUS  
 CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-(5,6-dihydro-6-  
 oxobenzo[c]-1,5-naphthyridin-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA  
 INDEX NAME)




RN 433726-78-4 CAPLUS  
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(2,5-diazabicyclo[2.2.1]hept-2-  
 yl)-  
 (9CI) (CA INDEX NAME)




RN 433726-82-0 CAPLUS

CN Acetamide, 2-chloro-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-  
(9CI) (CA INDEX NAME)




RN 433726-83-1 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-4-oxido-1-piperazinyl)-  
1-oxide (9CI) (CA INDEX NAME)




RN 433726-84-2 CAPLUS


CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-(1-pyrrolidinyl)-1-  
piperidinyl]-  
(9CI) (CA INDEX NAME)




RN 433726-85-3 CAPLUS  
 CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-  
 4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 433726-87-5 CAPLUS  
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-[(tetrahydro-2-furanyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 433726-88-6 CAPLUS  
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-(1-methylethyl)-1-piperazinyl]-  
 (9CI) (CA INDEX NAME)




RN 433726-89-7 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-cyclopentyl-1-piperazinyl)-  
(9CI) (CA INDEX NAME)




RN 433726-90-0 CAPLUS

CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-  
yl)-  
(9CI) (CA INDEX NAME)




RN 433727-88-9 CAPLUS  
CN Benzo[c]-1,5-naphthyridine-2,6-dione, 1,5-dihydro-, monohydrobromide  
(9CI)  
(CA INDEX NAME)




● HBr


RN 433727-90-3 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-4-oxido-1-piperazinyl)-  
(9CI) (CA INDEX NAME)



RN 433727-91-4 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-1,4-dioxido-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 433727-92-5 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-(cyclopropylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 433727-93-6 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433727-94-7 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-(cyclopropylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433727-95-8 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-acetonitrile, 5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433727-96-9 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-acetic acid, 5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-, ethyl ester, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433727-97-0 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(2,5-dimethylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


INDEX  
NAME)

Absolute stereochemistry.




RN 433727-98-1 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(4-fluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433727-99-2 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(4-methoxyphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA  
INDEX  
NAME)


Absolute stereochemistry.



RN 433728-00-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(3,4-dimethylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 433728-01-9 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(3,4-dichlorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 433728-02-0 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(2-fluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-03-1 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(3-methylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-04-2 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(3-chlorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-05-3 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(2-methylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-06-4 CAPLUS


CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(2-chlorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433728-07-5 CAPLUS  
CN Benzoic acid, 4-[(1S,4S)-5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433728-08-6 CAPLUS  
CN Benzoic acid, 3-[(1S,4S)-5-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433728-09-7 CAPLUS  
CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(4-methylphenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-10-0 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(4-phenylmethoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-11-1 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[(1S,4S)-5-[(3-fluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433728-12-2 CAPLUS


CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-(2-pyridinylmethyl)-1-

piperazinyl]- (9CI) (CA INDEX NAME)




RN 433728-13-3 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-[4-(3-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 433728-14-4 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-(dimethylamino)-, hydrochloride (5:6) (9CI) (CA INDEX NAME)




6/5 HCl

RN 433728-15-5 CAPLUS  
CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-  
, monohydrochloride (9CI) (CA INDEX NAME)




RN 433728-16-6 CAPLUS  
CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-  
4-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 433728-17-7 CAPLUS  
CN 1(2H)-Pyridineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-3,6-dihydro- (9CI) (CA INDEX NAME)




RN 433728-18-8 CAPLUS  
CN 2H-Isoindole-2-acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 433728-19-9 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-(dipentylamino)- (9CI) (CA INDEX NAME)




RN 433728-20-2 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 433728-21-3 CAPLUS


CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-[(2-phenylethyl)(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 433728-22-4 CAPLUS  
 CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 433728-23-5 CAPLUS  
 CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-2-(dipropylamino)- (9CI) (CA INDEX NAME)




RN 433728-24-6 CAPLUS  
 CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)-4-oxo- (9CI) (CA INDEX NAME)




RN 433728-25-7 CAPLUS

CN Acetamide, 2-(dibutylamino)-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 433728-26-8 CAPLUS


CN 4-Morpholineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 433728-27-9 CAPLUS  
CN 1H-Imidazole-1-acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 433728-28-0 CAPLUS  
CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-(dimethylamino)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 433728-29-1 CAPLUS  
CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-, hydrochloride (9CI) (CA INDEX NAME)




x HCl

RN 433728-31-5 CAPLUS  
CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-4-(1-pyrrolidinyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 433728-30-4  
CMF C23 H27 N5 O2




CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 433728-32-6 CAPLUS  
CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-4-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 433728-33-7 CAPLUS  
CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[[2-(1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 433728-34-8 CAPLUS  
 CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[(3-(1-methyl-2-pyrrolidinyl)propyl)amino]- (9CI) (CA INDEX NAME)



RN 433728-35-9 CAPLUS  
 CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[(2-(2-pyridinyl)ethyl)amino]- (9CI) (CA INDEX NAME)




RN 433728-36-0 CAPLUS  
 CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[(3-(3-pyridinyl)ethyl)amino]- (9CI) (CA INDEX NAME)




RN 433728-37-1 CAPLUS  
 CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-

4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 433728-38-2 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[1,5-c]naphthyridin-3-yl)-2-[(2-(4-morpholinyl)ethyl)amino]- (9CI) (CA INDEX NAME)




RN 433728-39-3 CAPLUS

CN Acetamide, 2-[(2-(diethylamino)ethyl)amino]-N-(5,6-dihydro-6-oxobenzo[1,5-c]naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 433728-40-6 CAPLUS


CN Acetamide, N-(5,6-dihydro-6-oxobenzo[1,5-c]naphthyridin-3-yl)-2-[(2-(dimethylamino)ethyl)amino]- (9CI) (CA INDEX NAME)




RN 433728-41-7 CAPLUS  
CN Acetamide, 2-[(3-(diethylamino)propyl)amino]-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 433728-42-8 CAPLUS  
CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[(3-(dimethylamino)propyl)methylamino]- (9CI) (CA INDEX NAME)




RN 433728-43-9 CAPLUS  
CN 1H-1,4-Diazepine-1-acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)hexahydro- (9CI) (CA INDEX NAME)



RN 433728-44-0 CAPLUS  
CN 1-Piperazineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-4-methyl- (9CI) (CA INDEX NAME)




RN 433728-45-1 CAPLUS  
CN 1-Piperazineacetamide, 4-(1,3-benzodioxol-5-ylmethyl)-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 433728-46-2 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[(2-oxo-1-pyrrolidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 433728-47-3 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-[(2-(1-piperidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 433728-48-4 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 2-(4-methyl-1-piperazinyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 433726-76-2


CMF C17 H18 N4 O



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 433728-50-8 CAPLUS

CN Acetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 433728-51-9 CAPLUS

CN 1-Piperidineacetamide, N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)-(9CI) (CA INDEX NAME)




IT 433728-81-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)  
(prepn. of benzazepinones, isoquinolinones and related compds. as  
inhibitors of poly(ADP-ribose) polymerase (PARP))

RN 433728-81-5 CAPLUS

CN Acetamide, 2-chloro-N-(5,6-dihydro-6-oxobenzo[c]-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 2001:162346 CAPLUS

DN 134:359384

TI Photoreaction of 2-Halo-N-pyridinylbenzamide: Intramolecular Cyclization Mechanism of Phenyl Radical Assisted with n-Complexation of Chlorine Radical

AU Park, Yong-Tae; Jung, Chang-Hee; Kim, Moon-Sub; Kim, Kwang-Wook; Song, Nam Woong; Kim, Dongho

CS Department of Chemistry, Kyungpook National University, Taegu, 702-701, S. Korea

SO Journal of Organic Chemistry (2001), 66(7), 2197-2206


CODEN: JOCEAH; ISSN: 0022-3263

PB American Chemical Society

DT Journal

LA English

GI




AB The photochem. of 2-halo-N-pyridinylbenzamide I (R = H, Cl, Br; R1 = H, Me; R2 = 4-N-(4-pyridynyl), 3-N-(3-pyridynyl), 2-N-(2-pyridynyl)) and chlorobenzanilide I (R = Cl, R1 = H, R2 = CH) was studied in aq. acetonitrile. The photoreaction of 2-chloro-N-pyridinylbenzamides produced photocyclized products, benzo[c]naphthyridinones in high yield, whereas the bromo analogs produced extensively photoreduced products, N-pyridinylbenzamides with minor photocyclized product. Since the photocyclization reaction of 2-chloro-N-pyridinylbenzamide was retarded by the presence of oxygen and sensitized by the presence of a triplet sensitizer, acetone or acetophenone, a triplet state of the chloro analog was involved in the reaction. Since several radical intermediates, particularly n-complexes of chlorine radical, were identified in the laser flash photolysis of 2-chloro-N-pyridinylbenzamide, an intramol. cyclization mechanism of Ph radical assisted with n-complexation of chlorine radical for the cyclization reaction was proposed: the triplet state (78 kcal/mol) of the chloro analog, which was populated by the excitation underwent a homolytic cleavage of the C-Cl bond to give Ph and chlorine radicals; while chlorine radical holded the neighbor pyridinyl ring with its n-complexation, the intramol. arylation of the Ph radical with the pyridinyl ring proceeded to produce a conjugated 2,3-dihydropyridinyl radical and then the conjugated radical aromatized to afford a cyclized product, benzo[c]naphthyridinone by ejecting a hydrogen. The photoredn. product can be formed by hydrogen atom abstraction of the Ph .sigma. radical from the environment.

IT 94191-07-8P, Benzo[c][1,5]naphthydrin-6(5H)-one

RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)  
(cyclized photoproduct; photolysis of halopyridinylbenzamide derivs.)


RN 94191-07-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one (9CI) (CA INDEX NAME)




RE.CNT 35      THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 AN 2000:879316 CAPLUS  
 DN 134:193358  
 TI Alkylbenzonaphthyridinones and benzonaphthyridinium quaternary salts  
 AU Dondela, B.; Sliwa, W.  
 CS Institute of Chemistry, Pedagogical University, Czestochowa, 42-201,  
 Pol.  
 SO Chemistry of Heterocyclic Compounds (New York) (Translation of Khimiya  
 Geterotsiklicheskikh Soedinenii) (2001), Volume Date 2000, 36(7), 830-  
 836  
 CODEN: CHCCAL; ISSN: 0009-3122  
 PB Consultants Bureau  
 DT Journal  
 LA English  
 AB Methyl- and ethylbenzonaphthyridinones, along with  
 ethylbenzonaphthyridinium iodides, 2,5-dimethyl-1,5-  
 benzo[c]naphthyridinium iodide, and isomeric N-(3-  
 bromopropyl)benzonaphthyridinium bromides were synthesized and their  
 structures were confirmed by <sup>1</sup>H NMR. Two of the obtained compds.  
 exhibited antibacterial activity.  
 IT 327096-09-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation) (prepn. and antibacterial  
 activity)  
 RN 327096-09-3 CAPLUS  
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 5-methyl- (9CI) (CA INDEX NAME)



IT 327096-11-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of benzonaphthyridinones and benzonaphthyridinium salts)  
 RN 327096-11-7 CAPLUS  
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one, 5-ethyl- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 AN 1985:45857 CAPLUS  
 DN 102:45857  
 TI Palladium-catalyzed cyclization of 2-substituted halogenoarenes by dehydrohalogenation  
 AU Ames, D. E.; Opalko, A.  
 CS Chem. Dep., Chelsea Coll., London, SW3 6LX, UK  
 SO Tetrahedron (1984), 40(10), 1919-25  
 CODEN: TETRAB; ISSN: 0040-4020  
 DT Journal  
 LA English  
 OS CASREACT 102:45857  
 GI



AB Cyclodehydrohalogenation mediated by Pd catalysts and solvents with different bases (the most satisfactory system being  $\text{Pd}(\text{OAc})_2$  in  $\text{AcNMe}_2$  with  $\text{Na}_2\text{CO}_3$  as base) has been examd. as a route to some heterocyclic systems. Whereas dehydrogenative cyclization processes require stoichiometric amts. of  $\text{Pd}(\text{II})$  reagent, the present procedure involves only catalytic amts. (0.1M proportion, or less), of Pd compd. The prepn. of dibenzofuran, carbazole, fluorenone, phenanthridone, 6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide (I), 6H-dibenzo[b,d]pyran and benzofuran[2,3-b]pyridine derivs. is described. The cyclization of 3-benzamido-2-chloropyridine (II) to 6-hydroxybenzo[c][1,5]naphthyridine (III) illustrates the regiospecificity of the process.


IT **94191-07-8P**  
 RL: FORM (Formation, nonpreparative); PREP (Preparation)  
 (formation of, by palladium-catalyzed cyclization of benzamidochloropyridine)

RN 94191-07-8 CAPLUS  
 CN Benzo[c]-1,5-naphthyridin-6(5H)-one (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 AN 1976:180196 CAPLUS  
 DN 84:180196  
 TI 4-Substituted amino-2,6-dioxo-pyrido[3,2-c]isoquinoline derivatives  
 IN Kobayashi, Goro  
 PA Kohjin Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 5 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 51011797	A2	19760130	JP 1974-81726	19740718
	JP 57040832	B4	19820830		
PRAI	JP 1974-81726		19740718		
GI					




I




II

AB The pyridoisoquinoline was prepd. by reaction of the methylthio deriv. II with H2NCH2CH(OEt)2. I had sedative and anticonvulsant activities (no data). Thus, fusion of 2 mmoles II with 5 mmoles H2NCH2CH(OEt)2 at 150.degree. for 1 hr gave 85% I.  
 IT **54706-14-8P**  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 54706-14-8 CAPLUS  
 CN Benzo[c]-1,5-naphthyridine-3-carbonitrile, 4-[(2,2-diethoxyethyl)amino]-1,2,5,6-tetrahydro-2,6-dioxo- (9CI) (CA INDEX NAME)



IT **54706-44-4**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 RN 54706-44-4 CAPLUS  
 CN Benzo[c]-1,5-naphthyridine-3-carbonitrile, 1,2,5,6-tetrahydro-4-(methylthio)-2,6-dioxo- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS  
AN 1975:72760 CAPLUS  
DN 82:72760

TI Heterocyclic ketenethioacetal derivatives. IV. Reactions of 1,2,3,4-tetrahydro-1,3-dioxoisouquinoline and 1,2,3,4-tetrahydro-1,4-dioxoisouquinoline with ketenethioacetals and reaction of these products

AU Ueno, Seiichi; Tominaga, Yoshinori; Matsuda, Yoshiro; Kobayashi, Goro

CS Fac. Pharm. Sci., Nagasaki Univ., Nagasaki, Japan

SO Chemical & Pharmaceutical Bulletin (1974), 22(11), 2624-34  
CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB Reaction of 1,3-dioxo- or 1,4-dioxo-1,2,3,4-tetrahydroisoquinolines with ketene thioacetals, e.g., (MeS)2C:C(CN)CO2Me, gave the corresponding substitution products, e.g., I, in good yields. The application of these

reactions afforded pyrano[2,3-c]isoquinoline and pyrrolo[1,2-b]isoquinoline, III (Z = O), derivs. The reaction of I and related compds. with amines afforded recyclized products, 2-benzopyranopyrano[3,4-

b]pyridine derivs., e.g. II. The reaction of III (Z = O) with amines gave

amino derivs., e.g., III (Z = NNH2). The reaction of IV with aminoacetal

afforded an aminoacetal deriv. which was treated with HCl to give a cyclized product V. The cyclization of derivs. of III (Z = O) with Et orthoformate or HCO2H gave pyrimidine derivs.

IT **54706-14-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(prepn. and cyclization of)

RN 54706-14-8 CAPLUS

CN Benzo[c]-1,5-naphthyridine-3-carbonitrile, 4-[(2,2-diethoxyethyl)amino]-1,2,5,6-tetrahydro-2,6-dioxo- (9CI) (CA INDEX NAME)



IT **54706-44-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(prepn. and reaction with sulfuric acid)

RN 54706-44-4 CAPLUS

CN Benzo[c]-1,5-naphthyridine-3-carbonitrile, 1,2,5,6-tetrahydro-4-(methylthio)-2,6-dioxo- (9CI) (CA INDEX NAME)




IT **54706-45-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)


RN 54706-45-5 CAPLUS

CN Benzo[c]-1,5-naphthyridine-3-carboxamide, 1,2,5,6-tetrahydro-4-(methylthio)-2,6-dioxo- (9CI) (CA INDEX NAME)




Reference(s):

1. Dondela, B.; Sliwa, W., Chem.Heterocycl.Compd.(Engl.Transl.), CODEN: CHCCAL, 36(7), <2000>, 830 - 836, Khim.Geterotsikl.Soedin., CODEN: KGSSAQ(7), <2000>, 944 - 950; BABS-6266153



Reference(s):


1. Dondela, B.; Sliwa, W., Chem.Heterocycl.Compd.(Engl.Transl.), CODEN: CHCCAL, 36(7), <2000>, 830 - 836, Khim.Geterotsikl.Soedin., CODEN: KGSSAQ(7), <2000>, 944 - 950; BABS-6266153



L10 ANSWER 1 OF 2 MARPAT COPYRIGHT 2003 ACS  
 AN 128:180325 MARPAT  
 TI Preparation of dibenzofuranoxobutyrates and analogs as matrix  
 metalloproteinase inhibitors  
 IN Sliskovic, Drago Robert; Picard, Joseph Armand  
 PA Warner-Lambert Company, USA; Sliskovic, Drago Robert; Picard, Joseph  
 Armand  
 SO PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806711	A1	19980219	WO 1997-US12389	19970716
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9737293	A1	19980306	AU 1997-37293	19970716
	EP 923569	A1	19990623	EP 1997-934175	19970716
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	JP 2000516607	T2	20001212	JP 1998-509712	19970716
	ZA 9707328	A	19980219	ZA 1997-7328	19970814
	US 6020366	A	20000201	US 1998-171833	19981027
PRAI	US 1996-24025P		19960816		
	WO 1997-US12389		19970716		

GI




AB Title compds. [I; R = CR<sub>6</sub>R<sub>7</sub>CH<sub>2</sub>CH(NR<sub>4</sub>R<sub>5</sub>)COR<sub>3</sub>; R<sub>1</sub>, R<sub>2</sub> = H, halo, alkyl, alkoxy, etc.; R<sub>3</sub> = OH, alkoxy, aryloxy, NHOH, etc.; R<sub>4</sub>, R<sub>5</sub> = H, alkyl, aryl, acyl, etc.; R<sub>6</sub> = H and R<sub>7</sub> = OH or SH; R<sub>6</sub>R<sub>7</sub> = O, S, NHO, NNH<sub>2</sub>, etc.]; Y = O, SOO-2, NR<sub>1</sub>, CH<sub>2</sub>, (NH)CO, etc.; W, W<sub>1</sub>, Z, Z<sub>1</sub> = CR<sub>1</sub> or N] were prep'd. Thus, dibenzofuran was acylated by N-trifluoroacetyl-L-aspartic acid anhydride to give (S)-R<sub>8</sub>COCH<sub>2</sub>CH(NHCOCF<sub>3</sub>)CO<sub>2</sub>H (R<sub>8</sub> = 2-dibenzofuryl). Data for biol. activity of I were given.


**MSTR 1A**



G9 = 8



G14 = 72-6 73-10




G15 = 88 / N




DER: and pharmaceutically acceptable salts and solvates  
 MPL: claim 1  
 STE: and isomers and stereoisomers


**MSTR 1B**



G9 = 5



G14 = 72-6 73-10



G15 = 88 / N





DER: and pharmaceutically acceptable salts and solvates  
 MPL: claim 1  
 STE: and isomers and stereoisomers

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 2 MARPAT COPYRIGHT 2003 ACS  
 AN 120:107044 MARPAT  
 TI Polycyclic heterocyclic agrochemical fungicides  
 IN Daub, John Powell; Finkelstein, Bruce Lawrence; Kleier, Daniel Anthony  
 PA du Pont de Nemours, E. I., and Co., USA  
 SO PCT Int. Appl., 138 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9314080	A1	19930722	WO 1992-US11329	19921230
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9334270	A1	19930803	AU 1993-34270	19921230
	EP 623125	A1	19941109	EP 1993-902842	19921230
	R: DE, DK, FR, GB				
	CN 1074443	A	19930721	CN 1993-100432	19930115
PRAI	US 1992-821724		19920115		
	WO 1992-US11329		19921230		

GI



AB The title fungicidal compds. I [A = direct bond, (un)substituted bridging group; Q = fused (un)substituted benzene, (un)substituted naphthalene, (un)substituted thiophene, (un)substituted furan, (un)substituted pyrrole, (un)substituted pyridine, (un)substituted pyrimidine ring; R1-R4 = H, halogen, CN, HO, C1-6 alkyl, C1-4 haloalkyl, C1-4 alkylthio, C1-4 alkylsulfinyl, etc.; X = N, CR4; Y, Z = N, CR5; R5 = H, halogen, C1-2 alkyl, C1-2 alkoxy; the total no. of heteroatoms in ring A are 1 to <math>\leq 2</math>] and their agriculturally suitable salts or metal complexes are prep'd., and I-contg. formulations presented. Thus, pyrimidine II was prep'd. (m.p. 166-166.5.degree.) and demonstrated antifungal activity against a variety of phytopathogenic fungi.


**MSTR 1C**



G10 = 41


4<sub>1</sub><sup>C</sup>—G11

G12 = 70-7 71-2



DER: or agriculturally suitable salts or metal complexes  
MPL: claim 1  
NTE: substitution is restricted  
STE: including all geometric and stereoisomers

=> d 11; d his; log y  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 11:56:51 ON 24 APR 2003)

FILE 'REGISTRY' ENTERED AT 11:57:01 ON 24 APR 2003

L1 STRUCTURE UPLOADED  
L2 7 S L1  
L3 94 S L1 FUL

FILE 'CAPLUS' ENTERED AT 11:57:28 ON 24 APR 2003

L4 6 S L3

FILE 'BEILSTEIN' ENTERED AT 11:58:01 ON 24 APR 2003

L5 0 S L1  
L6 6 S L1 FUL  
L7 2 S L6 NOT L3

FILE 'MARPAT' ENTERED AT 11:58:53 ON 24 APR 2003

L8 0 S L1  
L9 3 S L1 FUL  
L10 2 S L9 NOT L4

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	113.01	366.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
CA SUBSCRIBER PRICE ENTRY SESSION  
-1.24 -5.15

STN INTERNATIONAL LOGOFF AT 11:59:32 ON 24 APR 2003

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 1985:45857 CAPLUS

DN 102:45857

TI Palladium-catalyzed cyclization of 2-substituted halogenoarenes by dehydrohalogenation

AU Ames, D. E.; Opalko, A.

CS Chem. Dep., Chelsea Coll., London, SW3 6LX, UK

SO Tetrahedron (1984), 40(10), 1919-25


CODEN: TETRAB; ISSN: 0040-4020

DT Journal


LA English

OS CASREACT 102:45857


GI



I



II



III

AB Cyclodehydrohalogenation mediated by Pd catalysts and solvents with different bases (the most satisfactory system being  $\text{Pd}(\text{OAc})_2$  in  $\text{AcNMe}_2$  with  $\text{Na}_2\text{CO}_3$  as base) has been examd. as a route to some heterocyclic systems. Whereas dehydrogenative cyclization processes require stoichiometric amts. of  $\text{Pd}(\text{II})$  reagent, the present procedure involves only catalytic amts. (0.1M proportion, or less), of Pd compd. The prepn. of dibenzofuran, carbazole, fluorenone, phenanthridone, 6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide (I), 6H-dibenzo[b,d]pyran and benzofuran[2,3-b]pyridine derivs. is described. The cyclization of 3-benzamido-2-chloropyridine (II) to 6-hydroxybenzo[c][1,5]naphthyridine (III) illustrates the regiospecificity of the process.

IT 94191-07-8P

RL: FORM (Formation, nonpreparative); PREP (Preparation)  
(formation of, by palladium-catalyzed cyclization of  
benzamidochloropyridine)

RN 94191-07-8 CAPLUS

CN Benzo[c]-1,5-naphthyridin-6(5H)-one (9CI) (CA INDEX NAME)

